Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Maintenance therapy in AML

Tapan Kadia • 10 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Azacitidine Decitabine Gilteritinib Sorafenib Venetoclax

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives his thoughts on the use of maintenance therapy in patients with acute myeloid leukemia (AML). Dr Kadia notes the use of azacitidine (CC-486) as maintenance therapy in patients with AML, as well as a number of ongoing trials assessing other agents for maintenance therapy in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme

More from Tapan Kadia

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Jessica Altman et al. • 20 Sep 2025
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
2:35
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
2:47
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
Tapan Kadia • 8 Dec 2024
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
2:34
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals